The switch from trivalent to bivalent oral polio vaccine will take place between 17 April and 1 May 2016. During this time, 19 countries will phase out the trivalent OPV from their routine immunization schedules and begin using bivalent OPV only. The switch will have many benefits for the public health and will be a huge step in eradicating poliovirus.
Although the vaccine contains only attenuated strains of the poliovirus, it has the benefit of providing protection against all three serotypes. A single dose of trivalent OPV protects against all three types of the virus, while a single dose of bivalent OPV only protects against the two other types. While the trivalent vaccine is not 100% effective in eradicating polio, it does protect against one of these three strains.
In addition to being more effective in preventing polio, bivalent OPV has its own advantages. It is more affordable, is easier to administer, and is more effective against all three types of poliovirus. It is also safe for children. It is a proven way to eradicate polio in most countries. Further, it is highly cost-effective and is widely available.
In many countries, OPV has proven to be effective in preventing polio. This vaccine was used to prevent SIAs and has significantly helped the fight against the disease. The trivalent vaccine is effective against all three serotypes, while the bivalent vaccine contains just one of them. Therefore, it is important to switch from trivalent to bivalent OPV to avoid the risks associated with WPV.
The use of attenuated OPV in routine immunization is essential for eradicating poliovirus. However, it may not be safe for children to receive trivalent OPV. In contrast, bivalent OPV is more effective in preventing and treating polio. Regardless of which type of attenuated vaccine is used, the vaccine is highly effective against WPV1 and 3.
It is essential to choose a bivalent OPV. In this way, it will protect against both WPV1 and WPV3. During a SIA, a mix of attenuated vaccines is used. During an SIA, a trivalent vaccine was used to stop transmission of WPV1 and WPV3 but the disease was eliminated by 1999.